📊 CPHI Key Takeaways
Is China Pharma Holdings, Inc.. (CPHI) a Good Investment?
China Pharma Holdings exhibits severe financial distress with negative profitability across all metrics, collapsing revenue (-35.4% YoY), and critical liquidity constraints (0.35x current ratio). The company is burning cash operationally while carrying substantial debt, with no operational improvements or insider confidence evident in recent activity.
CHINA PHARMA HOLDINGS, INC. shows severely weak fundamentals, with sharply declining revenue, negative gross margin, and very large operating and net losses relative to sales. The balance sheet still has positive equity, but acute liquidity stress, minimal cash, and negative interest coverage materially increase financial risk and make the growth profile low quality.
Why Buy China Pharma Holdings, Inc.. Stock? CPHI Key Strengths
- Modest asset base of $15.8M provides some liquidation value
- Debt-to-equity ratio of 0.52x is relatively moderate given financial distress
- Active SEC reporting maintains transparency on deteriorating fundamentals
- Positive stockholders equity of $8.31M provides some residual balance-sheet support
- Debt/equity of 0.52x is not extreme relative to equity base
- Free cash flow loss is smaller than accounting losses, suggesting limited capital spending burden
CPHI Stock Risks: China Pharma Holdings, Inc.. Investment Risks
- Severe cash burn with negative operating cash flow (-$3.7K) and negative free cash flow (-$62.6K) threatens solvency within months
- Critical liquidity crisis with current ratio of 0.35x and only $267.6K cash against $7.5M liabilities creates immediate insolvency risk
- Revenue collapse of 35.4% YoY combined with negative gross margin (-9.7%) indicates fundamental business deterioration with no path to profitability
- Negative interest coverage (-100.0x) demonstrates inability to service debt obligations
- Zero insider Form 4 filings in 90 days suggests loss of management confidence
- Revenue declined 35.4% YoY, indicating major deterioration in demand or commercial execution
- Negative gross, operating, and net margins show the core business is currently unprofitable before and after overhead
- Current ratio of 0.35x, quick ratio of 0.10x, and cash of only $267.62K point to serious near-term liquidity pressure
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Quarterly revenue trends and gross margin recovery
- Debt covenant compliance and refinancing requirements
- Insider buying activity as confidence indicator
- Revenue stabilization and return to positive gross margin
- Cash balance and current ratio improvement
China Pharma Holdings, Inc.. (CPHI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CPHI Profit Margin, ROE & Profitability Analysis
CPHI vs Healthcare Sector: How China Pharma Holdings, Inc.. Compares
How China Pharma Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is China Pharma Holdings, Inc.. Stock Overvalued? CPHI Valuation Analysis 2026
Based on fundamental analysis, China Pharma Holdings, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
China Pharma Holdings, Inc.. Balance Sheet: CPHI Debt, Cash & Liquidity
CPHI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: China Pharma Holdings, Inc..'s revenue has declined by 58% over the 5-year period, indicating business contraction. The most recent EPS of $-2.71 indicates the company is currently unprofitable.
CPHI Revenue Growth, EPS Growth & YoY Performance
CPHI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $756.2K | -$528.4K | $-0.17 |
| Q2 2025 | $924.9K | -$528.4K | $-0.16 |
| Q1 2025 | $1.1M | -$785.6K | $-0.24 |
| Q3 2024 | $1.1M | -$476.0K | $-0.06 |
| Q2 2024 | $924.9K | -$476.0K | $-0.09 |
| Q3 2023 | $1.8M | -$476.0K | $-0.06 |
| Q2 2023 | $1.1M | -$593.0K | $-0.06 |
| Q1 2023 | $1.6M | -$476.0K | $-0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
China Pharma Holdings, Inc.. Dividends, Buybacks & Capital Allocation
CPHI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for China Pharma Holdings, Inc.. (CIK: 0001106644)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPHI
What is the AI rating for CPHI?
China Pharma Holdings, Inc.. (CPHI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPHI's key strengths?
Claude: Modest asset base of $15.8M provides some liquidation value. Debt-to-equity ratio of 0.52x is relatively moderate given financial distress. ChatGPT: Positive stockholders equity of $8.31M provides some residual balance-sheet support. Debt/equity of 0.52x is not extreme relative to equity base.
What are the risks of investing in CPHI?
Claude: Severe cash burn with negative operating cash flow (-$3.7K) and negative free cash flow (-$62.6K) threatens solvency within months. Critical liquidity crisis with current ratio of 0.35x and only $267.6K cash against $7.5M liabilities creates immediate insolvency risk. ChatGPT: Revenue declined 35.4% YoY, indicating major deterioration in demand or commercial execution. Negative gross, operating, and net margins show the core business is currently unprofitable before and after overhead.
What is CPHI's revenue and growth?
China Pharma Holdings, Inc.. reported revenue of $2.9M.
Does CPHI pay dividends?
China Pharma Holdings, Inc.. does not currently pay dividends.
Where can I find CPHI SEC filings?
Official SEC filings for China Pharma Holdings, Inc.. (CIK: 0001106644) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPHI's EPS?
China Pharma Holdings, Inc.. has a diluted EPS of $-0.57.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CPHI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, China Pharma Holdings, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CPHI stock overvalued or undervalued?
Valuation metrics for CPHI: ROE of -23.6% (sector avg: 15%), net margin of -67.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CPHI stock in 2026?
Our dual AI analysis gives China Pharma Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CPHI's free cash flow?
China Pharma Holdings, Inc..'s operating cash flow is $-3.7K, with capital expenditures of $58.9K. FCF margin is -2.1%.
How does CPHI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -67.3% (avg: 12%), ROE -23.6% (avg: 15%), current ratio 0.35 (avg: 2).